Boehringer Ingelheim International Gmbh

Link copied
Case Copied 17 min read

OFFICIAL NOTICE

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Application  :          No. 530174 in the name of BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Title:          Pharmaceutical Compositions

Action: Application for extension of term of a pharmaceutical patent under section 70 of the Patents Act.

Decision:          Issued             .

Abstract

The patentee requested an extension of term of the patent on the basis of marketing approval in relation to ATROVENT NASAL, which is a container adapted for nasal administration comprising an aerosol or spray composition of the active ingredient ipratropium bromide.

Claims 1 to 5, 11 and 12 define the combination of the container with the active agent composition and were not considered to define a pharmaceutical substance per se within the meaning of section 70(2)(a) nor were they considered to define a mixture or compound of substances. Claims 6 to 10 define a method of treatment, not a pharmaceutical substance. Claims 14 to 16, inserted as a result of amendment dated 28 September 1999, define an aerosol or spray composition as claimed in claim 1 when used in the container of claim 1. Such "when used" type claims have conventionally been construed as disguised process claims but, as such, they would not provide the basis for an extension of term of the patent. It was argued that they should be interpreted as product claims when used in the environment of the container. However, if this interpretation is accepted, in construing the claims as complying with section 102, they can only be to a product which is within the scope of the accepted claims and such claims have been found not to define a pharmaceutical substance per se.

Thus, it was found that none of the claims define a pharmaceutical substance per se as required by section 70(2)(a) and the application for extension of term was refused.

PATENTS ACT 1990

DECISION OF A DELEGATE OF THE COMMISSIONER OF PATENTS

Re:Patent Application No. 530174 by Boehringer Ingelheim International GmbH and an application under section 70 for an extension of term of a patent relating to pharmaceutical substances.

BACKGROUND

This matter concerns a request by the patentee, Boehringer Ingelheim International GmbH (hereafter referred to as Boehringer), for an extension of term of patent number 530174 under section 70 of the Patents Act 1990. Boehringer filed their request on 2 July 1999 indicating that this was in relation to the pharmaceutical substance ATROVENT NASAL (Ipratropium Bromide). The request was supported by a copy of the certificate of registration, showing the date of first regulatory approval (30 August 1995) and a printout showing that the substance was included in the Australian Register of Therapeutic Goods (ARTG). The 20 year term of the patent expired on 4 July 1999.

Boehringer were advised by letter from the Examiner dated 28 July 1999 that the identified substance did not meet the requirements of section 70(2)(a). They filed statements of proposed amendments dated 23 July 1999 and 28 September 1999. Leave to amend was granted on 1…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Boehringer Ingelheim International Gmbh and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2000] APO 18
Decision Date

CaseChat Overview and Summary

In the case of Boehringer Ingelheim International GmbH v Commissioner of Patents, the applicant sought an extension of term for a patent related to pharmaceutical substances. The patent in question pertained to ATROVENT NASAL, a nasal spray containing ipratropium bromide. The applicant argued that the patent met the criteria for an extension under section 70 of the Patents Act 1990, which allows for an extension of up to five years for pharmaceutical patents that are the subject of first inclusion on the Australian Register of Therapeutic Goods (ARTG).

The legal issues before the court revolved around whether any of the claims in the patent defined a "pharmaceutical substance per se" as required by section 70(2)(a) of the Patents Act. This section mandates that for a patent to be eligible for term extension, it must contain at least one claim covering a pharmaceutical substance per se. The applicant contended that the container comprising the aerosol or spray composition was the pharmaceutical substance per se.

The court examined the claims and concluded that none of them defined a pharmaceutical substance per se. Claims 1 to 5, 11 and 12 defined a container with an aerosol or spray composition, claims 6 to 10 defined a method of treatment, and claims 14 to 16 defined an aerosol or spray composition when used in the container. The court found that the combination of the container and the composition did not constitute a pharmaceutical substance per se, as it did not meet the definition of a substance, mixture, or compound of substances. Furthermore, the court determined that even if claims 14 to 16 were interpreted as product claims, they did not provide a basis for extending the term of the patent as they did not define a pharmaceutical substance per se.

Given that the court found none of the claims defined a pharmaceutical substance per se, it refused the application for an extension of term under section 70. Consequently, the applicant's request was denied.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established